Recombinant adeno-associated virus (AAV)-based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A major challenge for translation of promising research to clinical development is the manufacture and certification of AAV vectors for clinical use. This review summarizes relevant aspects of current Good Manufacturing Practice, focusing on considerations and challenges specific for recombinant AAV.
Overview of Good Manufacturing Practice
Recombinant adeno-associated virus (AAV) has demonstrated significant promise as a DNA-delivery vector to treat serious human diseases. Clinical studies using AAV vectors for the treatment of a1-antitryspin deficiency, Alzheimer's disease, arthritis, Batten's disease, Canavan's disease, cystic fibrosis, hemophilia B, HIV infection, Leber's congenital amaurosis, Parkinson's disease, muscular dystrophy, prostate cancer and malignant melanoma have been initiated. [1] [2] [3] The manufacture of clinical grade AAV vectors requires knowledge of the complex methods needed to generate, purify and characterize AAV vectors, combined with implementation of current Good Manufacturing Practice (cGMP), comprehensive procedural controls that have been developed to ensure clinical product quality, safety and consistency. A general description of cGMP for drug and biological products 4 and specific guidelines for Chemistry, Manufacturing and Controls information for gene therapy products are available. 5 For investigational new drugs (IND), the Food and Drug Administration (FDA)-drafted guidance documents describe an incremental approach to manufacturing controls be taken in a stagespecific manner during drug development. 6 Vector prepared for administration to human subjects must be produced according to cGMPs with due consideration for the nature of the material, manufacturing process and stage of clinical development. Controls and validated procedures that relate to clinical AAV vector safety must be established at the beginning of clinical product development. As clinical development progresses, the knowledge gained from manufacturing experience and product and process characterization studies should be reflected in refined cGMP controls. This incremental approach is based on recognition that some of the information and data required to validate manufacturing processes 7 and analytical methods 8 are obtained during the product development period. An important strategy to ensure adequate interpretation and stage-specific implementation of cGMP is to discuss plans for clinical manufacturing facility design, manufacturing processes and quality systems with the FDA.
Establishment of quality systems
A critical cGMP requirement is the establishment of controls to ensure quality and safety of investigational drug products, 9 including comprehensive quality systems that apply to all aspects of manufacturing, including staff training, raw materials qualification, vector generation and purification, quality control testing, and facility and equipment validation and maintenance. Detailed and comprehensive procedures must be written and followed, and record keeping during vector production and testing must be complete and accurate. An independent quality unit that is not involved directly in vector manufacturing must (1) inspect and release starting materials used in the manufacture of the product; (2) review and approve production and testing procedures and acceptance criteria; (3) release or reject clinical batches based upon review of completed records and (4) investigate errors and deviations from written procedures. While quality systems require that written procedures are in place and consistently followed, implementation of changes based on experience and good scientific rationale is also important to maintain best practices. Such changes must follow defined change control procedures, and early discussion of proposed changes with the clinical development team and regulatory authorities is important.
Manufacturing facility and equipment
The facility intended for clinical AAV vector manufacture must be appropriate for its use, providing adequate space, lighting, durable and easily cleanable surfaces, high-efficiency particulate-filtered air supply, and containment and air pressure balancing between individual rooms to protect staff from the product, and to protect the product from adventitious contamination. 10 The equipment used for the manufacturing process must be of suitable design, and constructed of high-quality components, and product-contact surfaces and materials must be appropriate for the preparation of human parenteral products. Before clinical vector manufacturing begins, as well as during manufacturing, data must be obtained to demonstrate that the facility is maintained at a specified level of cleanliness. 9, 10 Typically, cell culture and purification bioprocess steps can occur within sanitized, closed systems operating in a class 10 000 environment. Points in the process at which product intermediates are opened to the environment should occur in a class 100 environment such as a laminar airflow biosafety cabinet. Manufacturing staff must follow defined procedures including rigorous hygiene, and comprehensive gowning prior to entry of the manufacturing suite, typically using disposable sterile gowning components, to maintain cleanliness of the manufacturing environment. Detailed cleaning procedures must be developed and followed, and environmental monitoring of the manufacturing area and personnel is required on an ongoing basis to monitor the effectiveness of these procedures. Environmental monitoring is performed to assess total (that is, both inert and microbial) as well as viable (that is, microbial) particle counts in bioprocessing areas. Similar considerations apply to the preparation and assembly of sterile or appropriately sanitized product-contact materials, including tubing, filters, chromatography resins, and other product-contact surfaces. Processing equipment and product-contact materials can be purchased as certified sterile, one-time use (for example, tissue culture flasks, pipettes, bioprocess containers and tubing, filters) or otherwise sanitized prior to use (for example, chromatography resins, equipment product-contact surfaces) to ensure aseptic processing conditions. During product manufacturing, bioburden testing should be performed on samples taken at each process step to monitor for microbial contamination and provide documentation that process intermediates meet defined specifications. In a multiproduct facility, for example one intended to manufacture AAV vectors of varying serotype and/ or transgenes in sequential campaigns, specific intercampaign procedures including cleaning and equipment regeneration are required, demonstrating removal of the previous product. 4 
Clinical vector manufacturing processes

General considerations
For clinical product manufacturing, the cell culture and purification bioprocess methods implemented should be scalable, and consistently achieve high product safety, purity, potency and stability. Current state-of-the-art AAV production methods are described elsewhere in this issue. To achieve optimal safety, the methods and controls established must comply with regulations, be based on good science and ensure product quality by design. 11 Starting materials used for clinical vector generation and purification must meet rigorous and defined specifications, documented by recording specific lots used, retaining Certificates of Analysis and Origin. Starting materials that are animal derived should be avoided or minimized because they can be heterogeneous, incompletely defined, demonstrate significant variation and may harbor deleterious adventitious agents. If used, for example in the early stages of clinical product development, animal-derived products should be obtained from reliable sources with documented high levels of safety testing and characterization, and process development efforts should be initiated to replace them. Cell culture should be performed using culture media that is certified for use in the preparation of biologics, and not supplemented with antibiotics, providing a means to monitor aseptic technique and to ensure sterility during the cell-culture process steps. The use of antibiotics is likely to limit but not prevent contaminations that occur as a result of nonsterile techniques or reagents.
As a guideline, purity specifications can be based on those developed for licensed biologic products such as vaccines and recombinant proteins. Since AAV vectors generally aim to establish long-term gene expression, impurities that may contribute to immune responses limiting in vivo transgene expression should be identified and eliminated. Loss of therapeutic transgene-expressing cells due to AAV capsid-specific cytotoxic T lymphocytes was recently described in a clinical trial for hemophilia B, 12, 13 emphasizing the need to ensure that AAV vectors prepared for clinical use have low levels of potentially immunogenic impurities.
The manufacturing process should be developed and implemented at a scale appropriate to support the relevant stage of clinical development. Scalable process steps, that is, process steps for which performance is consistent and independent of scale, should be developed and implemented. While process scalability is a critical issue for commercial product development, product quality and safety should be the primary consideration. Vector generation and purification processes used for early phase clinical trials may include steps that are not readily amenable to scale up, but these should be the focus of process development efforts to establish full scalability as clinical product development proceeds.
With new technologies continuously emerging, for example, new cell-culture systems providing more efficient vector generation and better purification techniques with potential to enhance vector product quality and manufacturing scalability, changes in manufacturing processes should be expected during AAV vector product development. Early investment of resources to establish effective and scalable bioprocess steps is important to ensure sufficient quantities of vector, and to minimize changes to the manufacturing process. When process changes are implemented, the resulting vector product needs to be thoroughly characterized, with product comparability documented to ensure that safety and efficacy results observed at one phase of clinical development are valid for a subsequent phase.
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AAV-specific considerations: vector generation
Cell-culture systems that have been developed to generate AAV vectors include transient transfection of human cell lines, 15, 16 and infection of mammalian [17] [18] [19] [20] or insect cell lines, 21, 22 each providing certain advantages and limitations. Considerations for implementation of a cell-culture system for clinical AAV vector manufacturing include the following: (1) careful selection and rigorous qualification of biological reagents, (2) optimization of product yield and (3) optimization of vector biosynthesis methods to minimize the generation of product-related impurities.
AAV vector generation methods generally include a 'producer' cell type that provides the biosynthetic machinery for vector generation, combined with 'helper' vectors (for example, helper plasmids, helper viruses) as the source for additional required gene products. Each of these biological reagents must have a defined history, and be generated, characterized and stored in a manner to ensure safety, adequate supply and consistency of performance over a period of many years. An illustrative example is the generation of a master cell bank (MCB) of 'producer' cells. Significant time and resources are required to establish and qualify this critical starting material. Hence, it is prudent to compare available pre-MCB candidates for desirable features such as a complete history, documentation supporting freedom from contamination 23 and ability to support high vector productivity as a function of passage number, prior to establishing the cell bank. Once generated, the MCB is subjected to extensive characterization using validated test methods to verify identity and absence of viral and microbial contamination. 23 An example of characterization testing used to qualify an HEK293 MCB is shown in Table 1 . At early stages of a product development program, it is not unusual to use the MCB directly for vector production. However, a two-tiered cell bank composed of the MCB and working cell bank(s) derived from the MCB should be established in a timely manner to ensure a long-term supply of producer cells of consistent characteristics for vector generation. Analogous considerations are required for the establishment and qualification of the other biological components and reagents used in vector manufacturing. Plasmid DNA for use as a starting material in clinical AAV vector manufacturing should be designed to avoid the use of b-lactam antibiotics (for example, ampicillin) because of the potential sensitivity of recipients to residual antibiotic. 5 An important goal for the cell-culture/vector-generation method is to achieve consistent, high vector productivity. Measured as vector genomes (v.g.) generated per cell, AAV vector productivity can be highly variable, ranging from o10 3 to 2 Â 10 5 v.g. per cell. Besides the obvious benefit of higher cost-effectiveness, an important advantage of high productivity is that purification can be expected to be more efficient when the starting material has a higher ratio of the vector product to total harvest biomass. Inconsistent productivity means that vector must be purified from a variable amount of biomass, contributing to higher variability of impurities levels in the final purified product. Achieving consistent, high vector productivity during clinical vector manufacturing requires thorough 'upstream' process development and optimization studies combined with effective technology transfer to manufacturing staff.
Another important objective is design and optimization of the cell-culture system to minimize the generation of nonvector virus subpopulations and other productrelated impurities, including wild-type/pseudowildtype AAV species (wtAAV), AAV-encapsidated residual DNA impurities and empty capsids. Such productrelated impurities closely resemble the vector itself, and cannot easily be separated from bona fide vectors during the purification process. Wild-type AAV, while not a human pathogen, may lead to expression of viral antigens, contributing to activation of anti-AAV capsid immune responses and clearance of vector-transduced cells. The formation of wtAAV during vector biosynthesis can involve homologous or nonhomologous 24, 25 recombination events between AAV inverted terminal repeats (ITRs), and rep and cap sequences present in trans in helper components or producer cells. Elimination of overlapping sequences in production components, 26 inactivation or replacement of the p5 promoter region implicated in deleterious recombination events 15 and/or separation of AAV rep and cap sequences 25 can be implemented to prevent wtAAV species formation.
A second undesirable product-related subpopulation, AAV-encapsidated DNA impurities, correspond to heterogeneous fragments of host cellular or helper DNAs, likely containing sequences that inadvertently act as weak packaging signals for AAV. Theoretical concerns associated with such residual DNA impurities include their potential to express oncogenes derived from producer cell DNA, antibiotic resistance genes derived from helper DNA and sequences derived from producer cells and/or helper components encoding immunogenic polypeptides. The relative risks associated with such species are expected to depend upon the vector generation system used (that is, mammalian vs insect producer cells). Packaged residual DNA impurities derived from vector template and helper sequences were reported to range from 1 to 8% of total DNA in purified vector particles. [27] [28] [29] A significant portion of the encapsidated residual DNA is derived from the ITR-containing vector template, arising from 'reverse' packaging from the ITRs. Our laboratory has observed that the use of an 'oversized' plasmid backbone, that is, exceeding the 4.7 kb natural packaging limit of AAV, reduces residual plasmid DNA approximately fivefold (unpublished data). While these sequences are of concern, one study reported that residual plasmid DNA impurities in highly purified AAV2 vectors were not transcribed. 30 Packaging of fragments of mammalian producer cell-genomic DNA has been demonstrated to occur at levels range from B1% of total DNA in highly purified vectors to B3% in vectors that are co-purified with empty capsids. 27 For residual host cell DNA, the current regulatory guideline for biologics is o10 ng per dose. 31 Further reduction of AAV-encapsidated DNA impurities is an important objective for clinical manufacturing process development.
A third product-related impurity, AAV empty capsids, is generated at high levels in current AAV vector generation systems. For AAV2, empty capsid generation typically corresponds to 50-95% of total AAV particles generated in cell culture. 32 The cell-culture parameters that influence the level of empty capsid generation are Manufacturing and characterizing AAV-based vectors JF Wright not well understood. Our laboratory has observed that vector transgene cassettes that exceed the natural packaging capacity of AAV (B4.7 kb) result in higher empty capsid generation (unpublished data). Other factors are also involved based on the observation that empty capsid generation can vary widely between independent preparations of a single vector. 32 The presence of empty capsids was recently reported to enhance AAV6 vector transduction of muscle tissue in vivo. 33 However, Parker et al. 34 reported that transgene expression was inhibited by the presence of empty capsids following high-dose (410 13 v.g. per kg) administration of AAV2 vectors to mouse liver, so the effect of empty capsids on efficiency of transduction may be tissue specific. Immune responses directed against AAV capsid resulted in recognition and elimination of transduced hepatocytes in a clinical trial using AAV2-hFIX, 12, 13 and peptides derived from empty capsids themselves have been demonstrated to gain access to major histocompatibility complex class I presentation pathways. 35 To limit potential deleterious immune responses to AAV capsids it is prudent to minimize the generation of empty capsids in cell culture and/or substantially remove them during clinical vector purification (discussed below).
AAV-specific considerations: vector purification
Ideally starting from a cell harvest containing high levels of the vector product, the objective of the vector purification process is recovery of recombinant AAV of high purity, potency, safety and stability. A series of independent, orthogonal process steps should be developed to achieve high purity, each step achieving separation of AAV vectors from impurities based on different physicochemical parameters such as size, charge and density. AAV vectors resemble large, stable, symmetrical proteins, and many of the purification process development challenges to efficiently separate Manufacturing and characterizing AAV-based vectors JF Wright vector particles from impurities are similar to those that have been developed for proteins. 36, 37 For cGMP manufacturing, the process implemented should be high yielding, and demonstrated to perform consistently. The use of sterile, single-use product contact materials certified for use in the preparation of human biologics is recommended to help ensure aseptic processing and consistency. Product-contact materials that are used more than once, such as chromatography resins, must be demonstrated to perform in a reproducible manner over the planned cycles of use, and be sanitized and maintained to assure aseptic processing.
A description of the wide range of methods that have been developed to purify AAV vectors and are amenable to manufacture of a clinical product is beyond the scope of this review. However, three scalable bioprocess methodologies that our laboratory has found useful for AAV purification in a cGMP environment, cell disruption by microfluidization, micro-and ultrafiltration technologies, and column chromatography, are described briefly below. Recombinant AAV is largely retained within producer cells following its generation, and methods to release intracellular vector include physical and chemical disruption. Physical disruption of HEK293 cells by microfluidization is an efficient process that involves passage of vector-containing cells through a smalldiameter fluid path (interaction chamber) under high pressure. The release of vector can be enhanced by elevated ionic strength (for example, 300 mM NaCl), likely inhibiting ionic bond formation between vector particles and cell debris. Microfluidization also effectively shears cellular DNA, reducing viscosity and facilitating clarification. A theoretical concern with this method is that the high shear forces generated damage the vector particles. Based on experience involving multiple preparations of recombinant AAV2 using three sequential cycles of microfluidization for cell lysis, vector infectivity titers (9.3 ± 5.0 IU per v.g.) were not significantly different than titers measured for vectors prepared utilizing three freeze-thaw cycles to achieve cell lysis (6.4±3.2 IU per v.g.). 38 Parameter that should be defined and controlled to achieve consistent performance include interaction chamber input pressure, number of cycles required to achieve full cell disruption and temperature of operation.
Filtration technologies are useful to separate AAV vector from larger particles such as cell debris (microfiltration) as well as from smaller molecules such as soluble protein impurities (ultrafiltration). As an example, vector-containing cells that have been mechanically disrupted can be passed through a two-stage 0.45/ 0.2 mm cartridge filter to separate AAV vectors that are recovered in the filter permeate from cell debris, which is retained by the filter. This type of filtration can readily be used to clarify large volumes of AAV vector-containing process material by selection of appropriately sized, single-use cartridge filters to avoid clogging. Another important mode of filtration, tangential flow filtration (TFF), is a scalable, bioprocess industry-standard method that can be used to achieve volume reduction and purification of AAV vectors. TFF formats such as hollow fibers and 'plate and frame' systems, designed and constructed of materials appropriate for purification of human biologics, are widely available. Recombinant AAV vectors are significantly larger (B5000 kDa) than many soluble proteins and other impurities expected to be present in a cell harvest, providing a basis for separation by ultrafiltration. For example, TFF performed on an AAV vector-containing cell-culture harvest or other process intermediate using a 100K M r cutoff can achieve (1) B10-fold concentration of vector; (2) removal of soluble impurities that permeate through the membrane pores, separated from the retained vector and (3) efficient buffer exchange to facilitate subsequent process steps. TFF cartridges may be amenable to processing of several subbatches of an AAV vector product. If multiple use is considered, comprehensive performance qualification studies are required documenting effective cleaning, regeneration, sanitization and consistency in performance up to a defined maximum number of cycles.
Column chromatography, a well-established method used for efficient and scalable purification of biomolecules, is an important component for processes used to prepare AAV vectors for clinical studies. Using established method development strategies, chromatographic methods can be expected to separate AAV particles from most impurities in a clarified cell lysate. For most types of chromatography, customized conditions must be defined for differing serotypes because each serotype has unique surface-charge features. The discovery that membrane-associated heparin sulfate proteoglycan is a receptor for AAV2 39 facilitated the development of heparin-based affinity column chromatography purification methods for AAV2 vectors, 18, 40, 41 and the identification of 2,3-linked sialic acid moieties as ligands for AAV4 and AAV-5 has facilitated development of chromatographic methods for these serotypes. [42] [43] [44] Ion-exchange chromatography has been reported for purification of AAV vectors derived from serotypes 2, 4, 5 and 8. [45] [46] [47] [48] Implementation of chromatography methods for clinical vector purification processes requires similar material and performance qualification studies (for example, to support multiple subbatches) as discussed previously. A specific challenge for AAV purification is the removal of product-related impurities. AAV empty capsids, and some AAV-encapsidated DNA impurities are amenable to separation from vector using highresolution purification methods such as ion-exchange chromatography. Qu et al. 49 reported that high-resolution cation-exchange chromatography can resolve AAV2 and AAV6 vectors from their respective empty capsids. The mechanism responsible for separation the empty capsids and vectors appears to be related to a slightly increased negative charge density associated with DNA-containing vector particles compared to empty particles. Others have reported low empty capsid contents in AAV5 vector purified by ion-exchange chromatography. 45, 50 Davidoff et al. 51 reported the used of ion-exchange membranes to purify AAV8 vectors, containing less than 10% empty capsids in the final preparations based on electron microscopic analysis. Development of scalable, high-resolution purification techniques to remove product-related impurities is an important and challenging objective for AAV vector purification process development.
Viral clearance
Manufacturing processes for biologics must be designed to inactivate or 'clear' known infectious agents that are Manufacturing and characterizing AAV-based vectors JF Wright used to generate the product (for example, recombinant adenovirus, herpesvirus) as well as unknown, adventitious viral contaminants. 23 One tragic example of the consequences of failure to fully validate an inactivation process was the inadvertent infection of thousands of healthy recipients with live poliovirus following administration of an investigational inactivated poliomyelitis vaccine in 1955, resulting in severe paralysis in 164 individuals. 52 Physicochemical features of recombinant AAV, including its small size, thermal stability and absence of an envelope, which distinguish it from most pathogenic viruses, can be exploited for viral clearance. For example, AAV vector product intermediates can be subjected to elevated temperature or exposed to detergent to inactivate heat-sensitive adenoviruses or detergent-sensitive (enveloped) herpesvirus, respectively. General viral clearance should also be demonstrated over multiple vector purification steps. Such viral clearance studies typically involve spiking of representative AAV purification process intermediates with model viruses corresponding to differing virus families, and assessing the fold-reduction over individual process steps. The product of fold-reduction of a model virus titer over independent process steps is used to calculate the cumulative virus reduction. For example, 10 15 -fold clearance of a given virus can be achieved by three process steps each achieving 10 5 -fold reduction. Examples of model viruses that have been used in viral clearance studies are listed in the Federal Register. 23 
Formulation and vialing
The final stage of the vector manufacturing process is formulation and vialing of the purified vector product. Excipients should ensure vector stability under anticipated storage conditions, and be compatible with the expected route of administration. 53, 54 For some AAV serotypes, aggregation is known to occur when vectors are concentrated, 55 and should be avoided. Aggregation of biologic products may contribute to their unexpected loss during handling, and to altered biodistribution and increased immunogenicity following clinical administration. 56 Another concern is that 'typical' concentrations of purified AAV vectors (for example, 10 11 -10 13 v.g. per ml) correspond to dilute solutions of drug substance (B1-100 mg ml À1 ), and nonspecific adsorption of vectors to plastics, glass, metal and other surfaces during storage and handling of vector may occur. Inclusion of a surfactant in the drug product has been reported to prevent vector losses. 57 The critical final step in the preparation of the vector is to have the clinical vector filled into vials under validated aseptic conditions. 10, 58, 59 Facilities, equipment, procedures and personnel must be appropriate, and the filling process should be qualified prior to the actual product fill. 10 
Product characterization
AAV vectors prepared to support clinical research must be thoroughly characterized, meeting predetermined specifications pertaining to vector identity, safety, purity, potency and stability. 5, 60 A suggested set of AAV vector product release assays for Phase I clinical studies is shown in Table 2 . In addition, sequencing of AAV vector lots prepared for clinical use must be performed to verify identity and expected nucleotide sequence. It is important to include appropriate references in quality controls assays to ensure that results obtained are valid and reproducible, including a previously characterized AAV reference material that is assayed in parallel with the test article. Quality control methods used to ensure absence of microbial and adventitious viral contaminants in starting materials, intermediates and final vector product must be validated for all stages of clinical development. For some product-specific assays to measure purity and potency, a progressive approach for assay development and validation during clinical product development can be used. All quality control assays must be finalized and validated for Biologics License Application.
Safety
Safety testing should include assays for sterility, mycoplasma, endotoxin, general safety (for licensure only) and adventitious viral agents (AVA). Sensitive, validated tests to demonstrate the absence of mycoplasma and AVA must be performed on samples of crude cell harvest, the point at which such contaminants would be most readily detected. Sterility testing must be performed on the final product according to 21CFR 610.12. 4 Endotoxin testing should be performed on the final product using a validated assay, and acceptance criteria for endotoxin must be appropriate for the intended route of administration. Bioburden testing is recommended at product intermediate stages, for example following each purification step, to build assurance of aseptic conditions throughout the manufacturing process. Testing for wtAAV can be performed using an infectious center assay. 25 Establishment of the wtAAV assay for some serotypes is challenging due to the low infectivity of some serotypes in cultured cells. Assay development efforts to address this challenge must be prioritized when developing new serotypes for clinical studies, and early discussion with FDA is recommended to define and implement an appropriate strategy for clinical product development.
Purity
Levels of cell-culture process impurities, including residual host cell proteins and DNA, helper virus protein and nucleic acids, and helper plasmid DNA should be measured. For proteins, relevant methods include polyacrylamide gel electrophoresis and protein staining, reverse-phase high-pressure liquid chromatography, host-cell protein enzyme-linked immunosorbent assay (ELISA) and spectrophotometry. Nucleic acid impurities can be quantified by quantitative PCR (qPCR) using appropriately designed primers and probes. Removal of reagents that are added during the manufacturing process, for example nucleases added to degrade nucleic acid impurities, must be demonstrated using specific and sensitive methods. Assays that are used to characterize IND-supporting preclinical studies (for example, product efficacy and toxicity studies in animals) and early phase clinical studies should be developed and characterized so that data demonstrating assay sensitivity, linearity, accuracy, precision and specificity are obtained and well documented. Sensitive and specific assays to characterize product-related impurities should be part of clinical product testing. Levels of nuclease-resistant, AAVencapsidated DNA impurities can be assessed by qPCR
Manufacturing and characterizing AAV-based vectors JF Wright using primers and probes designed for relevant sequences in helper plasmids, or to high copy number genomic sequences. Sensitivity to nuclease treatment performed prior to qPCR allows distinction between nuclease-sensitive 'naked' residual DNA impurities and nuclease-insensitive-encapsidated residual DNA impurities. Total AAV capsids can be measured using capsidspecific ELISA assays and the amount of empty capsid determined by comparison of the capsid particle titer and the v.g. titer. Spectrophotometric methods can be used for samples in which non-AAV capsid impurities have been substantially removed. 32 
Potency
Measurement of the potency of purified AAV vectors typically includes assays to measure the concentration as well as functional activity. Nuclease-resistant genome concentration can be performed by dot blot hybridization or by qPCR, the latter method offering better robustness and amenability to standardization and validation. An important consideration when using qPCR to quantify AAV genomes is use of a linearized DNA template (for example, linearized plasmid DNA) to generate a standard curve. 32 The use of supercoiled DNA standards results in a significant overestimate of v.g. concentration. In addition to genome concentration, assays must be developed to assess the functional activity of vectors. For early phases of clinical studies, demonstration of transgene protein expression (for example, by ELISA) in a dose-dependent manner following transduction of an appropriate cell line may be acceptable. However, to support Phase III clinical trials, the expectation is that a bioassay will be established that quantifies functional activity of the transgene product. A supplemental approach to assess functional activity of AAV vectors is by quantification of infectivity. 38, 61 For all cell-based assays, identification of cell lines that are susceptible to AAV vectors of some serotypes is problematic, requiring significant assay development efforts.
Stability
Formal stability studies are required as part of the characterization of vectors prepared for clinical studies. 5, 62 These studies are required to verify that purified clinical vectors maintain their purity, potency and safety profiles during storage over the course of their potential use as investigational drugs. For early phase clinical studies, stability studies can be concurrent with clinical use. The stability profile of the final product, as 
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Manufacturing and characterizing AAV-based vectors JF Wright well as product intermediates, should be well defined by Phase III.
In conclusion, the potential for recombinant AAVbased gene transfer to address human disease is great. A critical component for translation from the research bench to clinic development, the manufacture and characterization of AAV vectors requires careful planning and diligent efforts in facility and process design, and rigorous quality systems. These efforts are required to ensure the safety and quality of this promising biologic product, and its success in clinical studies.
